Arteriovenous malformation (AVM) is an abnormal tangle of blood vessels connecting arteries and veins, which disrupts normal blood circulation and oxygenation. AVMs are most commonly detected in the brain and spinal cord, though they can develop in other parts of the body as well. Treatment of AVMs aims to eradicate the tangled vascular formation in order to restore normal blood flow and prevent life-threatening hemorrhaging. Embolization and surgical resection are two key approaches employed for AVM treatment. The global AVM treatment market offers a wide range of advanced embolic agents, surgical tools and navigation systems that facilitate the targeted elimination of these vascular anomalies.

The arteriovenous malformations market is estimated to be valued at USD 3.14 Bn in 2024 and is expected to reach USD 4.99 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.

Rising incidence rates of AVMs is a key factor propelling the Arteriovenous Malformation Market growth. Genetic predisposition, head injuries and certain rare disorders have been linked to higher risks of developing these vascular defects. With growing global geriatric demographic, the pool of high risk population is widening. This is boosting the clinical significance of AVM treatment. In addition, rising health awareness and availability of advanced treatment solutions are encouraging more patients to seek therapy. Improving reimbursement scenarios particularly in developing nations is also providing market opportunities.

Get More Insights On- Arteriovenous Malformation Market